Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
Objective: To assess the preemptive effect of Bepanthen® on decreasing the incidence of specific ≥ grade 2 dermatological side effects of interest in respect of compliance to EGFRI agents, HRQoL and the adherence during the 6-week skin treatment period. The adherence to the study creams will also be studied.
Epistemonikos ID: 8e7219711328b95f59efec8ab456e42ef03fbd15
First added on: May 05, 2024